# Shirô Nakamura

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/shiro-nakamura/

## Facts

| Field | Value |
| --- | --- |
| Citations | 5,294 |
| Field | Inflammatory Bowel Disease |
| h-index | 36 |
| i10-index | 119 |
| Last Known Institution | Osaka University of Pharmaceutical Sciences |
| OpenAlex ID | https://openalex.org/A5062739693 |
| ORCID iD | 0000-0003-4435-1294 |
| Works | 387 |

## Researcher papers

- [Evidence-based clinical practice guidelines for inflammatory bowel disease 2020](https://scholariq.org/papers/evidence-based-clinical-practice-guidelines-for-inflammatory-bowel-disease-2020/)
- [In situ expression of the cell adhesion molecules in inflammatory bowel disease. Evidence of immunologic activation of vascular endothelial cells.](https://scholariq.org/papers/in-situ-expression-of-the-cell-adhesion-molecules-in-inflammatory-bowel-disease/)
- [GC/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis](https://scholariq.org/papers/gc-ms-based-profiling-of-amino-acids-and-tca-cycle-related-molecules-in/)
- [Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn’s disease](https://scholariq.org/papers/multicenter-analysis-of-fecal-microbiota-profiles-in-japanese-patients-with/)
- [Scheduled infliximab monotherapy to prevent recurrence of Crohnʼs disease following ileocolic or ileal resection: A 3-year prospective randomized open trial](https://scholariq.org/papers/scheduled-infliximab-monotherapy-to-prevent-recurrence-of-crohn-s-disease/)
- [An increase in LRRK2 suppresses autophagy and enhances Dectin-1–induced immunity in a mouse model of colitis](https://scholariq.org/papers/an-increase-in-lrrk2-suppresses-autophagy-and-enhances-dectin-1-induced-immunity/)
- [Differential expression of mucosal addressin cell adhesion molecule‐1 (MAdCAM‐1) in ulcerative colitis and Crohn's disease](https://scholariq.org/papers/differential-expression-of-mucosal-addressin-cell-adhesion-molecule-1-madcam-1/)
- [NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study](https://scholariq.org/papers/nudt15-codon-139-is-the-best-pharmacogenetic-marker-for-predicting-thiopurine/)
- [The impact on health and risk factors of the diarrhoea epidemics in the 1998 Bangladesh floods](https://scholariq.org/papers/the-impact-on-health-and-risk-factors-of-the-diarrhoea-epidemics-in-the-1998/)
- [The structures of anisatin and neoanisatin](https://scholariq.org/papers/the-structures-of-anisatin-and-neoanisatin/)
- [Six-Month Safety and Effectiveness of Teduglutide in Patients with Short Bowel Syndrome in Japan: Interim Analysis of Post-marketing Surveillance](https://scholariq.org/papers/six-month-safety-and-effectiveness-of-teduglutide-in-patients-with-short-bowel/)

## Researcher topics

- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)
- [Microscopic Colitis](https://scholariq.org/topics/microscopic-colitis/)
- [Autoimmune and Inflammatory Disorders](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders/)
- [Helicobacter pylori-related gastroenterology studies](https://scholariq.org/topics/helicobacter-pylori-related-gastroenterology-studies/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)

## Researcher university

- [Osaka University of Pharmaceutical Sciences](https://scholariq.org/institutions/osaka-university-of-pharmaceutical-sciences/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.